<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687882</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00063928</org_study_id>
    <secondary_id>1U01HL130048-01A1</secondary_id>
    <nct_id>NCT00687882</nct_id>
  </id_info>
  <brief_title>Evaluation of the Duration of Therapy for Thrombosis in Children</brief_title>
  <acronym>Kids-DOTT</acronym>
  <official_title>Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins All Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins All Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Kids-DOTT trial is a randomized controlled clinical trial whose primary objective is to
      evaluate non-inferiority of shortened-duration (6 weeks) versus conventional-duration (3
      months) anticoagulation in children with first-episode acute venous thrombosis. The first
      stage of the trial has consisted of a pilot/feasibility component, which then continues as
      the definitively-powered trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children (birth to 21 years of age, inclusive) with first-episode venous thrombosis in
      association with a reversible clinical trigger (key exclusions: history of cancer; severe
      thrombophilia state disclosed) are enrolled and prescribed anticoagulation according to the
      clinical standard of care and American College of Physicians (Chest journal) 2012
      recommendations. At the 6 week (post-diagnosis) follow-up visit, repeat radiologic imaging is
      performed to determine residual thrombus burden and its degree of occlusion. In addition,
      those subjects with antiphospholipid antibodies (APA) disclosed at enrollment will undergo
      repeat APA testing.

      Patients with residual occlusive thrombosis or persistent APA are excluded from
      randomization, and followed on parallel cohort arms (observational), with conventional
      anticoagulation durations. All other patients are randomized to a total anticoagulant
      duration of 6 weeks versus 3 months. Children are followed for primary efficacy endpoints of
      symptomatic recurrent venous thromboembolism (VTE) and primary safety endpoints of
      clinically-relevant bleeding (major plus clinically-relevant non-major, as per International
      Society of Thrombosis and Haemostasis Scientific and Standardization Committee [Journal of
      Thrombosis &amp; Haemostasis] 2012 definitions/recommendations).

      Children are followed through 2 years (with primary endpoint at 1 year). Those with deep
      venous thromboses affecting venous return from the limbs also undergo standardized
      post-thrombotic syndrome (PTS) outcome assessment using the Manco-Johnson pediatric PTS
      instrument.

      The non-inferiority analysis uses a bivariate endpoint approach, modeling the inherent
      clinical trade-off between the risks of recurrent VTE and bleeding. The trial will enroll 750
      children across 40 participating centers, and allows for a 25% rate of exclusion from the
      per-protocol population due to randomization non-eligibility (i.e. parallel cohort),
      withdrawal/loss to follow-up, and protocol non-adherence.

      A sub-study, completed in late 2013, used investigational dalteparin in lieu of formulary low
      molecular weight heparin (typically enoxaparin) in those children who were clinically
      prescribed a low molecular weight heparin for sub-acute anticoagulation. The goal of this
      sub-study was to report dose-finding and outcomes data in children treated with dalteparin
      for VTE. Outcomes in these patients were qualitatively compared with those of patients who
      received enoxaparin, warfarin, or other anticoagulants for sub-acute anticoagulation. This
      portion of the study was an industry-sponsored investigator-initiated sub-study with an
      investigator-held IND. Since the closure of the sub-study, the overall Kids-DOTT study is no
      longer conducted under an Investigational New Drug (IND) application.

      Principal aims and hypotheses:

      Specific Aim #1: To evaluate the efficacy and safety of shortened-duration (6 weeks total)
      versus conventional-duration (3 months total) anticoagulation for first-episode, provoked,
      acute venous thrombosis among children in whom thrombus resolution/non-occlusion (i.e.
      established blood flow) is evident after the initial 6 weeks of anticoagulant therapy

      Hypothesis: Among children with first-episode, provoked, acute venous thrombosis in whom
      thrombosis is resolved or non-occlusive at six weeks follow-up, a shortened duration of
      anticoagulation (total six weeks; i.e. no further therapy) is non-inferior in efficacy to the
      conventional duration (total three months) of anticoagulation with respect to the risk of
      symptomatic recurrent VTE at 1 year, and is superior in safety with respect to the risk of
      clinically-relevant bleeding.(The hypothesis will also be tested in secondary analysis at 2
      years, using the same efficacy and safety outcomes as for the 1 year primary analysis.)

      Specific Aim #2: To determine whether outcomes of first-episode, provoked, acute venous
      thrombosis (specifically, with respect to recurrent VTE and PTS) among children treated with
      conventional-duration (3 months total) anticoagulation differ between those with and without
      thrombus resolution/non-occlusion at 6 weeks.

      Hypothesis: Among children with first-episode, provoked, acute venous thrombosis treated with
      conventional-duration (3 months total) anticoagulation, the cumulative incidences of
      recurrent VTE and PTS are significantly lower among those in whom thrombus
      resolution/non-occlusion was, versus was not, evident after the initial 6 weeks of
      anticoagulant therapy.

      Specific Aim #3: To establish a clinical trial-derived plasma and nucleic acids biorepository
      for future proteomic, genomic, and metabolomic investigations of predictors and modulators of
      VTE outcomes in children.

      Specific Aim #4 (Exploratory Aim): To evaluate whether the effect of treatment duration on
      the risks of symptomatic recurrent VTE and clinically-relevant bleeding in children with
      first-episode, provoked, acute venous thrombosis differs substantively between subgroups
      defined by type of sub-acute anticoagulant therapy in real-world clinical use (all prescribed
      clinically, with the exception of investigational dalteparin, which was prescribed under an
      investigator-held IND through December 2013).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bivariate endpoint.</measure>
    <time_frame>1 Year</time_frame>
    <description>Primary efficacy endpoint is the risk of symptomatic, radiologically-confirmed recurrent venous thromboembolism.
Primary safety endpoint is clinically-relevant bleeding (major + clinically-relevant non-major).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence/severity of post-thrombotic syndrome.</measure>
    <time_frame>1 and 2 Years</time_frame>
    <description>PTS is measured using a standardized validated pediatric outcome instrument (Manco-Johnson instrument). Both PTS and clinically-significant PTS will be captured as secondary endpoints.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">815</enrollment>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Intervention: A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parallel Cohort: Persistent Occlusive Thrombosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with completely occlusive thrombosis at 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parallel Cohort: Persistent Antiphospholipid Antibody</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with persistent Positive Antiphospholipid Antibody at 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Shortened duration (6 weeks) of anticoagulant therapy</intervention_name>
    <description>Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 6 weeks.</description>
    <arm_group_label>Intervention: A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional duration (3 months) of anticoagulant therapy</intervention_name>
    <description>Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 3 months.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>Subjects with evidence of persistent thrombus at 6 weeks time will remain on anticoagulant therapy for 3-6 months at the discretion of their treating physician.</description>
    <arm_group_label>Parallel Cohort: Persistent Occlusive Thrombosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>Subjects with evidence of persistent antiphospholipid antibody at 6 weeks will remain on anticoagulant therapy for 3 months to indefinite duration, at the discretion of their treating physician.</description>
    <arm_group_label>Parallel Cohort: Persistent Antiphospholipid Antibody</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children (birth to &lt;21 years of age) with radiologically-confirmed acute venous
             thrombosis in the past 30 days

          2. In the opinion of the investigator, the venous thrombosis was a provoked (i.e.,
             non-spontaneous) event (e.g.: hospitalization; Central venous catheterization;
             infection; dehydration; surgery; trauma; immobility; use of estrogen-containing oral
             contraceptive pills; flare of autoimmune/rheumatologic condition).

        Exclusion Criteria:

          1. Prior episode of VTE

          2. Malignancy that, in the opinion of the treating oncologist, is not in remission, or
             for which chronic anticoagulation is being administered/anticipated to be initiated
             within 6 months (note: remission may exist on or off anti-neoplastic therapy)

          3. Systemic lupus erythematosus

          4. Pulmonary embolism that is not accompanied by DVT or is more proximal than segmental
             branches of the pulmonary artery

          5. Use of, or intent to use, thrombolytic therapy

          6. History of congenital cardiac disease for which chronic anticoagulation is being
             administered/ anticipated to be initiated within 6 months (e.g., for select patients
             or centers, in the setting of a single or hypoplastic ventricle or
             surgically-established cardiac shunt)

          7. Moderate/severe anticoagulant deficiency as defined by any one of the following:

               1. protein C &lt;20 IU/dL if patient is ≥3 months of age, or protein C below lower
                  limit of detection if patient is &lt;3 months of age;

               2. antithrombin &lt;30 IU/dL if patient is ≥3 months of age, or antithrombin below
                  lower limit of detection if patient is &lt;3 months of age;

               3. protein S (free antigen or activity) &lt;20 IU/dL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil A Goldenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins All Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neil A Goldenberg, MD, PhD</last_name>
    <phone>727-767-6886</phone>
    <email>neil@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frances L Hamblin, MSHS, RN</last_name>
    <phone>727-767-2460</phone>
    <email>Frances.Hamblin@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Bemrich-Stolz</last_name>
      <email>cbstolz@peds.uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christy Patrick</last_name>
      <email>cpatrick@peds.uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lee Hillard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Portillo</last_name>
      <phone>323-361-2597</phone>
      <email>juanportillo@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Jaffray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Titi Singer, MD</last_name>
      <email>tsinger@mail.cho.org</email>
    </contact>
    <investigator>
      <last_name>Titi Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ofelia Vargas</last_name>
      <phone>714-509-8735</phone>
      <email>ovargas@choc.org</email>
    </contact>
    <investigator>
      <last_name>Arash Mahajarin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>34304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Macasiray</last_name>
      <email>emacasiray@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Clara Lo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Children's Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Surrell</last_name>
      <email>amsurrell@ucdavid.edu</email>
    </contact>
    <investigator>
      <last_name>Arun Panigrahi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehrzad Milburn</last_name>
      <email>mmilburn@rchsd.org</email>
    </contact>
    <investigator>
      <last_name>Courtney Thornburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>George Washington University, Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynnette Lee</last_name>
      <phone>904-697-2128</phone>
      <email>Lynnette.Lee@nemours.org</email>
    </contact>
    <contact_backup>
      <last_name>Ingrid Ingram</last_name>
      <email>Ingrid.Ingram@nemours.org</email>
    </contact_backup>
    <investigator>
      <last_name>Cindy Gauger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leandro Pisani</last_name>
      <phone>305-243-6925</phone>
      <email>lfp34@miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maria Santaella</last_name>
      <email>msantaella@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Fernando Corrales-Medina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna Davis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Barrett</last_name>
      <phone>727-767-3213</phone>
      <email>laurie.barrett@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jade Hanson</last_name>
      <email>Jade.Hanson@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Neil Goldenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University / Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Roberts</last_name>
      <phone>404-785-9856</phone>
      <email>Kristin.Roberts@choa.org</email>
    </contact>
    <contact_backup>
      <last_name>Lasandra Patterson</last_name>
      <email>lasandra.patterson@choa.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kavita Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Oftelie</last_name>
      <email>softelie@luriechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Trecia Malcolm</last_name>
      <phone>312-227-4825</phone>
      <email>tmalcolm@luriechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rukhmi Bhat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia and Thrombosis Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Summers</last_name>
      <phone>317-871-0011</phone>
      <phone_ext>218</phone_ext>
      <email>asummers@ihtc.org</email>
    </contact>
    <investigator>
      <last_name>Charles Nakar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Stead Family Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxanne Mitten</last_name>
      <phone>319-356-1212</phone>
      <email>roxane-mitten@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Anjali Sharathkumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tonya Shaffer</last_name>
      <phone>502-629-5604</phone>
      <email>tonya.shaffer@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Kerry McGowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Weiss</last_name>
      <phone>410-614-0050</phone>
      <email>dweiss14@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emily Jacobs</last_name>
      <phone>410-614-0052</phone>
      <email>ejacob29@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cliff Takemoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Addonizio</last_name>
      <phone>617-355-8733</phone>
      <email>kathryn.addonizio@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Cameron Trenor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan, Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Enderlan</last_name>
      <phone>313-966-8393</phone>
      <email>kenderle@dmc.org</email>
    </contact>
    <investigator>
      <last_name>Madhvi Rajpurkar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Carlson</last_name>
      <phone>517-432-5126</phone>
      <email>Laura.Carlson@hc.msu.edu</email>
    </contact>
    <investigator>
      <last_name>Ajovi Scott Emuakpor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen Devos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Gleason</last_name>
      <phone>616-391-5075</phone>
      <email>emily.gleason@helendevoschildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Bartleson</last_name>
      <phone>616-391-8534</phone>
      <email>jennifer.bartleson@helendevoschildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Deanna Mitchell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eryn Bilynsky</last_name>
      <phone>816-855-1768</phone>
      <email>erbilynsky@chm.edu</email>
    </contact>
    <investigator>
      <last_name>Shannon Carpenter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Horta</last_name>
      <email>chorta@barnabashealth.org</email>
    </contact>
    <investigator>
      <last_name>Shalu Narang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice J. Cohen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Ireland</last_name>
      <email>Kireland@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer Davila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>Ithaca</city>
        <state>New York</state>
        <zip>14850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Keefe</last_name>
      <phone>212-746-4933</phone>
      <email>pek2010@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Daniella Stern</last_name>
      <phone>646-962-8343</phone>
      <email>das2075@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nicole Kucine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine McGuinn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Bayer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Narine</last_name>
      <phone>718-470-3439</phone>
      <email>mnarine@nshs.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Maisel</last_name>
      <phone>718-470-4434</phone>
      <email>jmaisel1@northwell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Suchitra Acharya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Neunert</last_name>
      <phone>212-342-3853</phone>
      <email>cn2401@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Cindy Neunert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golisano Children's Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akua Asanta</last_name>
      <phone>585-275-2981</phone>
      <email>Akua_asante@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Criag Mullen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Bradisse</last_name>
      <email>jbradisse@chmca.org</email>
    </contact>
    <investigator>
      <last_name>John Fargo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Pilllow</last_name>
      <phone>513-636-6719</phone>
      <email>anngreene.pillow@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Paula Mobberley-Schuman</last_name>
      <phone>513-803-9255</phone>
      <email>Paula.Mobberley-Schuman@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Christina Tarango, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Muehle</last_name>
      <phone>216-983-3178</phone>
      <email>sally.muehle@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Sanjay Ahuja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myra Christian-Rancy</last_name>
      <phone>614-722-3690</phone>
      <email>Myra.Christian-Rancy@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Sarah O'Brien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Webber</last_name>
      <email>Linda-Weber@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Osman Kahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janna Journeycake, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Stokes</last_name>
      <phone>717-531-7765</phone>
      <email>jstokes1@hmc.psu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Beiler</last_name>
      <email>jbeiler@jhc.psu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Smita Dandekar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Cahill</last_name>
      <phone>215-427-4607</phone>
      <email>michele.cahill@tenethealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Camille Coleman</last_name>
      <phone>215-427-5104</phone>
      <email>camille.colman@tenethealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Deepti Raybagkar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Martino</last_name>
      <phone>412-692-6467</phone>
      <email>angela.martino2@chp.edu</email>
    </contact>
    <investigator>
      <last_name>James Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Warner</last_name>
      <email>Warmere@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Shayla Bergmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Lazarchick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palmetto Health</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Adams</last_name>
      <phone>803-434-3109</phone>
      <email>julia.adams@palmettohealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Staci Klotz</last_name>
      <phone>803-434-4328</phone>
      <email>Staci.Klotz@palmettohealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Stuart Cramer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Center of Central Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhea Robinson</last_name>
      <email>RMRobinson@seton.org</email>
    </contact>
    <investigator>
      <last_name>Robert Mignacca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Winborn</last_name>
      <phone>214-456-8185</phone>
      <email>Anna.Winborn@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Ayesha Zia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital (Baylor)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>81432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebbecca Perez</last_name>
      <phone>801-587-7759</phone>
      <email>Rebbecca.perez@hsc.utah.net</email>
    </contact>
    <investigator>
      <last_name>Anupam Verma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Wigginton</last_name>
      <phone>757-668-7909</phone>
      <email>Sabrina.Wigginton@chkd.org</email>
    </contact>
    <investigator>
      <last_name>Gary Woods, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin, Blood Center of Wisconsin</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville VIC</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodi Hislop</last_name>
      <email>Jodi.Hislop@rch.org.au</email>
    </contact>
    <contact_backup>
      <email>michele.hepponstall@rch.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Monagle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinishe Universitat Wien</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Wissman</last_name>
      <email>eva.wissman@meduinwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Christoph Male, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stollery Children's Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dory Sample</last_name>
      <email>dory.sample@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Patti Massicotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster Childrens Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Korinne Hamilton</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>76054</phone_ext>
      <email>hamiltonko@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Anthony Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SickKids</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Celeste Lumia</last_name>
      <email>celeste.lumia@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Leonardo Brandao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anelise Santo</last_name>
      <email>Anelise.Santo@juhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Christine Sabapathy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susanne Holzhauer, MD</last_name>
      <email>Susanne.Holzhauer@charite.de</email>
    </contact>
    <investigator>
      <last_name>Susanne Holzhauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Hebrew-University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilach Stencel</last_name>
      <phone>972-3-5307583</phone>
      <email>Lilach.Stencel@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Roni LeibaFisher</last_name>
      <email>Roni.LeibaFisher@sheba.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Gili Kenet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christa de Leeuw-Slingerland</last_name>
      <email>beheer.kocr@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Heleen Van Ommen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://www.hopkinsallchildrens.org/academics/research/multicenter-studies/kids-dott</url>
    <description>https://www.hopkinsallchildrens.org/academics/research/multicenter-studies/kids-dott</description>
  </link>
  <reference>
    <citation>Goldenberg NA, Tripputi M, Crowther M, Abshire TC, DiMichele D, Manco-Johnson MJ, Hiatt WR. The &quot;parallel-cohort RCT&quot;: Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. Contemp Clin Trials. 2010 Jan;31(1):131-3. doi: 10.1016/j.cct.2009.11.006. Epub 2009 Nov 24.</citation>
    <PMID>19941974</PMID>
  </reference>
  <reference>
    <citation>Kittelson JM, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Steg G, Turpie AG, Cutler NR, Hiatt WR, Goldenberg NA; Antithrombotic Trials Leadership and Steering (ATLAS) Group. Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach. J Thromb Haemost. 2013 Aug;11(8):1443-8. doi: 10.1111/jth.12324. Review.</citation>
    <PMID>23773172</PMID>
  </reference>
  <reference>
    <citation>Goldenberg NA, Abshire T, Blatchford PJ, Fenton LZ, Halperin JL, Hiatt WR, Kessler CM, Kittelson JM, Manco-Johnson MJ, Spyropoulos AC, Steg PG, Stence NV, Turpie AG, Schulman S; Kids-DOTT Trial Investigators. Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings. J Thromb Haemost. 2015 Sep;13(9):1597-605. doi: 10.1111/jth.13038. Epub 2015 Aug 11.</citation>
    <PMID>26118944</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2008</study_first_posted>
  <last_update_submitted>March 18, 2018</last_update_submitted>
  <last_update_submitted_qc>March 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Neil Goldenberg</investigator_full_name>
    <investigator_title>Director of Research and Chief Research Officer, Johns Hopkins All Children's Hospital</investigator_title>
  </responsible_party>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>Postthrombotic Syndrome</keyword>
  <keyword>Antithrombotic Therapy</keyword>
  <keyword>Duration of Therapy</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Antiphospholipid</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

